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       Hot melt extrusion (HME) is a leading technology that can be applied to many 
pharmaceutical preparations as solid dispersions. Part of this research project focus on 
injecting pressurized carbon dioxide (P-CO2) gas during the HME process. These 
combined techniques have an additional advantage of being adaptable and portable to a 
hot melt extruder instrument. The use of HME alongside with other techniques (P-CO2 or 
co extrusion process) for preparing an improved controlled/sustained release formulation 
is the main theme of this research project. Current research focusing on Active 
Pharmaceutical Ingredients (APIs) with good aqueous solubility requires novel approach 
to obtain tailored drug release for the processed sustained/controlled release formulations. 
HME, when combined with other novel techniques has been shown to be a practicable 
method for the development of novel floating drug delivery systems. This research also 
focused on the feasibility of HME/P-CO2 and HME/co extrusion techniques to prepare 
the intended formulation with specific properties with detailed explanation of the 
resulting dosage forms. Also, it explores the effects of different formulation variables and 
process parameters on the quality of final product. These studies of research facilitate the 
development of floating drug delivery devices, as well as improving the consistency of 
the powder flow while processing which result in with improved drug content with 
comparable sustained release profile to the marketed formulation.   
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The key objectives of this dissertation chapters are: (1) to introduce HME as an efficient 
technique alongside when combined with other novel techniques in pharmaceutical 
industry; (2) to prepare floating mini tablets of acetaminophen (APAP) with the 
hydrophobic carriers Eudragit® RL PO and Eudragit® RS PO by HME/P-CO2 and to 
evaluate the buoyancy efficiency through in-vitro methods. Moreover, scanning electron 
microscopy (SEM) was utilized to visually investigate the morphological change of the 
matrix; (3) to develop of sustained-released donepezil hydrochloride (DH) formulations 
with various hydrophobic carriers utilizing HME technique alone to optimize hot melt 
process parameters for obtaining the desirable sustained release profile ; (4) to develop 
and evaluate a sustained-release DH formulation with improved & consistent drug 
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CHAPTER 1: INTRODUCTION 
BREIF OVERVIEW   
            Hot-melt extrusion (HME) is not only commonly used technology in the plastic, 
rubber and food industry but also it has wide array of application in the pharmaceutical 
industry. HME is one of the most efficient technology to prepare solid dispersions. In 
HME process, the Active Pharmaceutical Ingredient (API) and the carrier matrix can be 
mixed/blended together to prepare a physical mixture that can be extruded under certain 
specific conditions as a feasible and continuous process (Patil, Tiwari, & Repka, 2015; 
Shah, Maddineni, Lu, & Repka, 2013a). The processing parameters such as feeding rate, 
shearing force, temperature, die geometry, barrel design, screw rotating speed should be 
considered as it may contribute significantly in the quality of the final product such as 
uniformity of size, shape and content. HME offers several advantages over other 
conventional methods for example, it is one-step solvent-free, giving a continuous 
operation, which has fewer processing steps, requires no compression and can improve 
bioavailability due to dispersion of the drug at the molecular level. However, there are 
few limitations which could restrict the use of HME in the pharmaceutical industry, for 
instance, it requires a higher energy input compared to other techniques and may exclude 
some thermo-labile compounds due to high processing temperatures (Crowley et al., 




     The popularity of the HME as a pharmaceutical technology has been increasing day 
by day and this is evidenced by increased number of worldwide patents issued, 
commercial pharmaceutical products and available research articles. It has been 
successfully used to prepare various pharmaceutical drug delivery systems such as pellets 
(Alshetaili et al., 2016), granules (J. Liu, Zhang, & McGinity, 2001), immediate and 
modified release tablets (Patil, Tiwari, Upadhye, Vladyka, & Repka, 2015), taste-masked 
oral fast dissolving systems (Alshehri et al., 2015), transdermal delivery systems (M a 
Repka, Gerding, Repka, & McGinity, 1999), transungual delivery systems (Mididoddi & 
Repka, 2007), solid lipid nanoparticle systems (Patil, Feng, Ye, Majumdar, & Repka, 
2014; Patil, Kulkarni, Majumdar, & Repka, 2014), nanocrystals (Khinast, Baumgartner, 
& Roblegg, 2013; Ye et al., 2015), and floating drug delivery systems (Bjad K. 
Almutairy et al., 2015; Fukuda, Peppas, & McGinity, 2006a). Floating drug delivery 
systems is one of the themes of this dissertation. These systems are utilized to increase 
the residence time of APIs within stomach. Increasing the gastric residence time of any 
dosage form can be achieved by recent approaches which include bio-adhesive systems 
that are increased in size upon swallowing, and low-density systems that float on the 
gastric fluids. To prolong the dosage form residence time, one of the following 
approaches is used: swelling system expanding systems, floating drug delivery systems, 
which also known as hydrodynamically balanced systems, bio-adhesive systems, high-
density systems, and delayed gastric emptying devices. The reason why we chose multi 
particulate system/multi units’ system is being helpful for fixed dose formulation that has 
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more than one API. 
 
EQUIPMENT 
 An extruder consists of a feeder, barrel with screws or ram, control panel, torque 
sensors, heating/cooling device, with dies. On-line and in-line quality control analysis 
using near-infrared (NIR) probe and other well-known analysis like Raman, ultrasonic 
and dielectric spectroscopy can be easily adapted with HME process (Alig, Fischer, 
Lellinger, & Steinhoff, 2005). Pharmaceutical screw extruders are designed based upon 
the regulatory guidelines to produce desired extrudates (shape and size). There are mainly 
three types of extruders: 1) single-screw extruder, 2) twin screw extruder and 3) multiple 
screw extruder. Among these types, twin screw extruder has been used widely in the 
pharmaceutical research and industry. There are two types of twin screw extruders. First 
one is high-speed energy input (HSEI) twin-screw extruder, which is mainly used for 
compounding, reactive processing and/or devolatilization. The second one is low-speed 
late fusion (LSLF) twin-screw extruders, which is designed to mix at low shear and pump 
at uniform pressures.  Twin-screw extruder has many advantages over single-screw 
extruder as it overcomes formulation mixing problem and provides complete mixing of 
the components. For higher capacity extruders, each zone has independent 
heating/cooling units and temperature sensors that can efficiently maintain the individual 
zones at preset temperatures. In addition, pressure arises due to the friction of the material 
inside the barrel and the resistance exerted by the material against the barrel walls assists 
the ejection of material through the die. The two screws can be oriented in a number of 
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configurations depending on the desired level of shear and speed of operation. These 
configurations setting can play a significant role in addressing some issue related to the 
formulation. For example, Morott et al. concluded that the screw configuration is a 
dependent parameter in the efficiency and stability of some taste-masked formulations. 
Through specific screw configuration, they have demonstrated that sildenafil citrate’s 
crystallinity can be preserved with successfully processed formulations (Morott et al., 
2015). In addition, Teixeira et al. have investigated algorithmic tools that are effective 
and required by industry. They determined the appropriate and adapted screw 
configurations for specific aims (Teixeira, Covas, Stützle, & Gaspar-Cunha, 2012). 
Depending to the required intensity of mixing, the two screws can be designed to rotate in 
the same direction (co-rotating) or in the opposite direction (counter-rotating). The 
counter-rotating designs are utilized when very high shear regions are needed as they 
impose materials to very high shear forces as the material is squeezed through the gap 
between the two screws as they come together. However, co-rotating screws are mainly 
used in pharmaceutical manufacturing (Crowley et al., 2007). 
 
DOWNSTREAM PROCESSING EQUIPMENT 
 Many formulations can be processed using melt extrusion technology. Scientists 
have many options for the selection of the preferring specific die shapes and sizes. Flat 
dies are used for production of films (M a Repka et al., 1999; Michael a Repka, 
Prodduturi, & Stodghill, 2003; Trey, Wicks, Mididoddi, & Repka, 2007) and patches 
(Palem et al., 2013), whereas circular dies are used for palletization and spheronization 
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(Alshetaili et al., 2016; R. V Tiwari, Patil, & Repka, 2016; Young, Koleng, & McGinity, 
2002). The molten drug-polymer mixture can also be filled into molds using injection 
molding. For instance, these molds can be formed to yield the tablet, capsule shapes, ear 
inserts or designed pediatric formulation (Patil, Tiwari, & Repka, 2015; Michael a Repka 
et al., 2012). Some of the dosage forms that have been studied previously are rods, film 
(M a Repka et al., 1999), pellets, spherical pellets (Alshetaili et al., 2016; Young et al., 
2002), punched tablets (Andrews et al., 2008; Verreck et al., 2005), injection molded 




HME processing parameters and addressing related mixing issues 
     From the general understanding of the processing, HME can be theoretically divided 
into five steps: i) feeding, ii) melting and plasticizing, iii) conveying and mixing, iv) 
venting and v) stripping and downstream processing. Each section may affect the 
properties of the final extrudates. These affected properties might arise an issue in the 
process, which needs to be fixed during the optimization stage. The material to be 
extruded is introduced into the feed section of extruder via a hopper. It is essential that 
the angle of the feed hopper is always exceeding the angle of repose of the feed material 
in order to assure good flow properties of the feedstock. Otherwise, there will be an 
arising issue, as the material tends to form a solid bridge at the neck of the hopper 
resulting in changeable flow. However, to address this issue, a force-feeding device such 
as a mass flow feeder or side stuffer can be used to run the feedstock onto the rotating 
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screw. Mixing is a potential factor during HME process and is classified as distributive 
mixing and dispersive mixing. Processing parameters play a key role in determining the 
properties of the extrudates. Some of the most commonly adjusted parameters include 
screw speed, processing temperature and feeding rate. The screw speed and feeding rate 
are also related to shear stress, shear rate and mean residence time, which will affect the 
dissolution rate and stability of the final products (Crowley et al., 2007; Mishra, 2016; R. 
V Tiwari et al., 2016). 
 
Screw design and configuration   
     The design and configuration of the screw have a significant impact on the process 
and can be selected to meet particular requirements such as high or low shear. Screws are 
designed with several sections, with the function of each section ranging from feeding, 
mixing, compression, and metering. To improve the melting process and mass flow 
through the extruder, modulating the screw design is sometimes potential factor (Morott 
et al., 2015). The efficiency of the melting process is highly dependent on the polymer’s 
properties and the extruder design. However, very few articles in the literature discuss the 
effects of screw design and configuration on HME processing. Morott et al. demonstrated 
that the screw configuration has an influence on the quality of the products when using a 
twin-screw extruder. Kneading paddle elements of the twin-screw extruder is another 
example. Nakamichi et al. demonstrated that they played an important role in changing 
the crystallinity and dissolution properties of a solid dispersion of kneaded nifedipine-
hydroxy propyl methyl cellulose phthalate (Nakamichi, Nakano, Yasuura, Izumi, & 
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Kawashima, 2002). Verhoeven et al. described that the distribution homogeneity and the 
release rate of metoprolol tartrate in ethyl cellulose mini-matrices were not significantly 
affected by the number of kneading mixing zones or their positions along the extruder 
barrel and that at least one kneading/mixing zone was required for homogenous 
distribution (Verhoeven, De Beer, Van den Mooter, Remon, & Vervaet, 2008). Liu et al. 
studied the effects of screw configuration on the dissolution behavior of indomethacin in 
Eudragit EPO melt extrudate. Further, they identified that the kneading blocks 
accelerated the complete dissolution process of indomethacin in polymer melt (H. Liu, 
Wang, Zhang, Shen, & Gogos, 2010). Thus, from the above-mentioned reports, it is clear 
and evident that HME processing parameters plays an important role in determining the 
properties of the extrudates.  
 
Process analytical technology (PAT) and scale up issues 
     PAT can be used as a tool to monitor, closely observe, analyze, and characterize melt 
extrusion and chemical composition of the products in line to ensure final desired product 
attributes. Using PAT as an analytical tool, flow properties, polymer structures, polymer-
drug interaction as well as concentrations of drugs and additives can be determined 
immediately downstream of the extrusion process (Alig et al., 2005).  Scaling-up in HME 
like other manufacturing technologies is an important subject of discussion. For scale up, 
the aspect of autogenous extrusion is also important since the ratio of surface to volume 
become more unfavorable with increasing extruder size, especially if the process has not 
been developed to run autogenously on a small scale. Increasing in the size of the 
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extruder can cause some issues such as variation in the ratio of surface to volume. As it is 
deliberated that extruder is aimed to be as closed system as a pipe with forced conveying 
by the extruder screw, the mean residence time can be as short as less than 30 seconds. 
The impact of process parameter on the residence time and torque should be known for 
each formulation to the respective extruder. This allows us for making better comparison 
and understanding the correlation (Maniruzzaman & Nokhodchi, 2016).  
 
Co-extrusion process 
This co-extrusion process solves the issues related with material impaired by individual 
extruded polymer layer. The process of extruding two or more materials through a single 
die with two or more orifices arranged so that the extrudates merge and join together into 
a laminar structure before chilling is called co-extrusion. The physical mixture is fed 
through the hopper to the extruder (separately), however the orifices is arranged in such a 
way that the material will be extruded through a common die thus creating a bilayer 
(Iosio et al., 2008) or multilayer end product (Mofidfar et al., 2016; Wang et al., 2014). 
An example for bilayer end product is the work that has been done by Iosio et al. (Iosio et 
al., 2008). The compositions of those two layers are microcrystalline cellulose, lactose 
and water along with wetted with the self-emulsifying system. Regarding multilayer, the 
final product obtained may be in the form of a laminar structure with multiple layers, 
which may offer several advantages due to material and composition characteristics 
imparted by the individual extruded polymer layer. The principle of co-extrusion shows 
promise for many novel dosage forms, including oral, transdermal and implants (Dierickx 
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et al., 2012, 2014; Quintavalle et al., 2008; Quintavalle, Voinovich, Perissutti, Serdoz, & 
Grassi, 2007; R. V Tiwari et al., 2016; Vynckier et al., 2014; Vynckier, Voorspoels, 
Remon, & Vervaet, 2016). 
 
Use of plasticizers as processing aids  
     Use of plasticizer into the formulations would aid to improve the processing 
conditions during the manufacturing of the extruded dosage form or to improve the 
physical and mechanical properties of the final product. Examples are triacetin, citrate 
esters, D-a-tocopheryl, and surfactants. Moreover, injection of pressurized CO2 during 
HME processing shows a reduction in processing temperatures of variety of polymers in 
producing extruded dosage form. In addition, pressurized CO2 acts as a foaming agent 
(Ashour et al., 2015). It has also been shown that CO2 acts as a plasticizer for PVP-VA 
64, Eudragit® E100 and Ethyl Cellulose 20 cps, allowing for a reduction in processing 
temperature(Verreck et al., 2006). Additionally, several drug substances have been 
reported to function as plasticizers in hot-melt extruded dosage forms. Repka et al (M a 
Repka et al., 1999) have studied the effect of chlorpheniramine maleate and 
hydrocortisone as plasticizers for hydroxy propyl cellulose films. These two APIs (1%) 
have shown a plasticizing property on that specific polymer. In addition, they provide 
mechanical stability to the films. Employing this technique has substantial effect in 
transdermal films. It gives a broader flexibility to films by the effect on polymer matrix. 
Some APIs have been utilized by their own plasticizing effect. For instance, Ibuprofen 
has been used in HME as a plasticizer in some formulations(De Brabander, Van Den 
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Mooter, Vervaet, & Remon, 2002). In addition, vitamin E TPGS has been utilized as an 
excellent processing aid It has been employed to successfully produce plasticized 
matrices (M. A. Repka & McGinity, 2000). 
 
Other processing aids 
     Hydroxy propyl cellulose (HPC) or ethyl cellulose (EC) may encounter oxidation 
effect when they expose to higher temperatures. Incorporation of an antioxidant, such as 
butylated hydroxytoluene or ascorbic acid, into these formulations is highly 
recommended. Similarly, a combination of an antioxidant, light absorber and acid 
acceptor is recommended for systems using EC.  PEO films have been reported to be 
protected from free radical and oxidative degradation by the incorporation of an 














CHAPTER 2:  
DEVELOPMENT OF FLOATING DRUG DELIVERY SYSTEM WITH SUPERIOR 
BUOYANCY IN GASTRIC FLUID USING HOT-MELT EXTRUSION COUPLED 
WITH PRESSURIZED CO2 
ABSTRACT 
The present study aimed to develop a continuous single-step manufacturing platform to 
prepare a porous, low-density, and floating multi-particulate system (mini-tablet, 4 mm 
size). This process involves injecting inert, non-toxic pressurized CO2 gas (P-CO2) in 
zone 4 of a 16-mm hot-melt extruder (HME) to continuously generate pores throughout 
the carrier matrix. Unlike conventional methods for preparing floating drug delivery 
systems, additional chemical excipients and additives are not needed in this approach to 
create minute openings on the surface of the matrices. The buoyancy efficiency of the 
prepared floating system (injection of P-CO2) in terms of lag time (0 sec) significantly 
improved (P < 0.05), compared to the formulation prepared by adding the excipient 
sodium bicarbonate (lag time 120 sec). The main advantages of this novel manufacturing 
technique include: (i) no additional chemical excipients need to be incorporated in the 
formulation, (ii) few manufacturing steps are required, (iii) high buoyancy efficiency is 
attained, and (iv) the extrudate is free of toxic solvent residues. Floating mini-tablets 
containing acetaminophen (APAP) as a model drug within the matrix-forming carrier 
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(Eudragit® RL PO) have been successfully processed via this combined technique (P-
CO2/HME). Desired controlled release profile of APAP from the polymer Eudragit® RL 
PO is attained in the optimized formulation, which remains buoyant on the surface of 
gastric fluids prior to gastric emptying time (average each 4 h). 
 
Keywords: Hot-Melt Extrusion, Pressurized CO2, Floating tablet, Acetaminophen, 
Eudragit® RL PO.  
 
2.1. Introduction 
Hot-melt extrusion (HME) is a leading technology for the manufacture of solid 
dispersions using polymers as matrix-forming carriers; various solid dosage forms can be 
manufactured using this process (Alshehri et al., 2015; Patil, Feng, et al., 2014; M. A. 
Repka et al., 2007). One of those solid dosage forms is that of a low-density based 
floating system (A. Streubel, Siepmann, & Bodmeier, 2002). Floating drug delivery 
systems developed by the pharmaceutical industry specialists are readily available (B. N. 
Singh & Kim, 2000). The advent of innovative techniques has ushered scientists into an 
era of increasingly productive and cost-effective manufacturing processes. In order to 
address the common limitations of conventional methods and to overcome the difficulties 
in formulating floating systems using these methods (Table 2-1) (Badawy & Hussain, 
2007; Fordtran, Morawski, Santa Ana, & Rector Jr., 1984; Forslund, Koistinen, Anttinen, 
Wagner, & Miettinen, 2008; Fukuda, Peppas, & McGinity, 2006b; Thomas & Stone, 
1994), a novel-manufacturing platform has been proposed and was compared with the 
13 
 
latest technique for manufacturing Floating Drug Delivery Systems (FDDS) (Patil, 
Tiwari, & Repka, 2015).  
Not only has HME gained increasing attention among industrial pharmacy researchers, 
recently, injecting pressurized carbon dioxide (P-CO2) gas during the HME process has 
also received much attention. Injecting P-CO2 gas during a solvent-free continuous HME 
process has an added advantage of being adaptable and portable to a hot melt extruder 
instrument (A. Ashour et al., 2015). 
Most of the conventional methods for preparing floating systems, such as the 
microsphere and gel formation floating method, depend on the use of organic solvents 
such as n-hexane, ethanol, methanol etc. (Choi, Park, Hwang, & Park, 2002; Dhaliwal, 
Jain, Singh, & Tiwary, 2008; Galeska et al., 2005; Silva, Ribeiro, Figueiredo, Ferreira, & 
Veiga, 2005; Thanoo, Sunny, & Jayakrishnan, 1993). The residual of these solvents can 
be hazardous to health upon long-term use. Another approach utilizes lipids as low-
density floating devices; however, instability and polymorphism of crystalline lipid 
matrices limits the use of these agents (Chauhan, Shimpi, Mahadik, & Paradkar, 2005). 
Additionally, using excipients such as sodium bicarbonate, while extruding the physical 
blend, affects the stability and compatibility of floating dosage compositions. This can be 
explained in terms of buoyancy efficiency. The buoyancy lag time for the device can be 
up to 3 min (Fukuda et al., 2006b). 
The gastric pH in some patients fluctuates and can reach a pH of up to 7.0, as seen in 
fasted achlorhydric subjects (Mathias et al., 2015; Russell et al., 1993). Prescribing a 
floating tablet to these patients would result in an increased lag time owing to the release 
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of CO2 from the traces of sodium bicarbonate (Fukuda et al., 2006b). Consequently, there 
is a risk that the floating device will escape out of the pyloric sphincter. Further, it will be 
expelled out of the stomach with chyme during gastric emptying (Hwang, Park, & Park, 
1998; Wei, Yu, & Bi, 2001). Other techniques that implement effervescent systems has a 
drawback, as the system does not float immediately after swallowing the dosage form, 
since the process of gas generation has a delayed lag time of up to 20 min. Therefore, 
they could be cleared from the stomach before becoming functionally effective 
(Alexander Streubel, Siepmann, & Bodmeier, 2006). Most of these systems are single 
unit devices (Hwang et al., 1998).  Therefore, they lose their benefits early before they 
have a chance to function as a floating system in gastric media due to their all-or-nothing 
emptying from the stomach. In order to address the aforementioned issues, a 
multiparticulate-unit floating system has been developed (Kawashima, Niwa, Takeuchi, 
Hino, & Ito, 1991). 
Acetaminophen (APAP) was selected as a model drug in the present study, since it 
is not a thermolabile active pharmaceutical ingredient (API) and it has been extensively 
used previously in developing various formulations via the HME technique (Qi, Gryczke, 
Belton, & Craig, 2008). Furthermore, it has a narrow absorption window and is absorbed 
in the upper intestinal segment (Davis, 2005) and it is also prescribed to patients to 
alleviate abdominal pain after the postoperative procedure (Hyllested, Jones, Pedersen, & 
Kehlet, 2002). All these properties make APAP a suitable candidate for developing 
floating systems. Eudragit® RL PO (EUD), is one of the polymers that has been widely 
used in HME processing (Saerens et al., 2011; Zheng, Cerea, Sauer, & McGinity, 2004; 
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Zhu, Shah, Malick, Infeld, & McGinity, 2006). It is a copolymer that has quaternary 
ammonium groups. These groups function as salts, increasing the permeability of 
dissolution media and make this hydrophobic carrier highly permeable. This permeability 
characteristic makes this polymer a good candidate to comply USP-NF monograph for 
the extended release preparations of APAP extended release profile specifications. 
In the current study, the HME/P-CO2 approach was used to develop a FDDS based 
on low-density devices. This single-step, cost-effective, continuous, and efficient 
combination method for manufacturing floating gastric devices overcomes the limitations 
of conventional methods. In this process, API and pH-independent polymer are used 
along with the injection of an inert P-CO2 gas. This study aimed to investigate the effect 
of injected inert CO2 gas on the physico-mechanical properties of the controlled-release 
hot-melt extrudates to obtain mini-tablets, using EUD as a release-retarding carrier which 
resulted in optimal buoyancy required for a floating device, compared to the devices 
prepared by the existing approach. 
 
2.2. Materials 
Acetaminophen was purchased from Mallinckrodt (St. Louis, MO, USA) and Eudragit® 
RL PO was kindly gifted by Evonik industries (Piscataway, USA). Sodium bicarbonate 
was purchased from Fisher Scientific (Hanover Park, IL, USA). CO2 gas cylinders (pure 
clean) were purchased from Airgas (902 Rockefeller St, Tupelo, MS 38801 USA). All 





2.3.1. Physical blend preparation and HME/P-CO2 process 
EUD was sieved (mesh size #35) and blended with 30% APAP with and without 
sodium bicarbonate using a V-shell blender (MaxiBlendTM, GlobePharma, North 
Brunswick, NJ, USA). The blends were dried in an oven overnight at 30 °C. The 
extrudates obtained were in the form of regular rods when only co-rotating twin-screw 
extruder (16 mm Prism Euro Lab, Thermo Fisher Scientific, Stone, UK) was used. When 
P-CO2 gas was injected at zone 4 of the extruder, the extrudates obtained were in the 
form of porous, foamy rods. With optimal torque (around 80%), all formulations (Table 
2-2) were extruded at an optimal processing temperature (Table 2-3). Tailoring the ratio 
of API/polymer in the formulations, along with the appropriate extrusion temperature 
profile, can be utilized to obtain neat and intact extrudate strands and to be convenient for 
further downstream procedures (i.e. mini tablet pelletization). P-CO2 was injected into the 
barrel of the extruder by means of a high-pressure regulator throughout an injection 
nozzle located in barrel segment 4 (Figure 2-1). CO2 gas was pressured and injected into 
the extruder using a high-pressure regulator connected to pliable stainless-steel hose with 
an armor case ending up in a four-way connection with a pressure gauge, check valve, 
and bleed valve connected to the injection port at zone number 4 of the extruder. P-CO2 
gas (120 psi) was metered and regulated using a knob. The obtained extrudates were then 
cut into mini-tablets (4 mm diameter) using a pelletizer (Type L-001-9482, Thermo 




2.3.2. Scanning electron microscopy (SEM) 
The surface morphology of the mini tablets was studied by SEM. Samples were 
mounted on adhesive carbon pads placed on aluminum stubs. Gold was used to coat the 
samples by a Hummer® 6.2 sputtering system (Anatech LTD, Springfield, VA) in a high-
vacuum evaporator. A scanning electron microscope was operated at an accelerating 
voltage of 5 kV for imaging (JEOL JSM-5600). 
 
2.3.3. Density measurements and porosity calculation 
True density of powdered solid dispersion for all the formulations as well as the 
pure polymer with and without P-CO2 has been measured. True density of milled solid 
dispersion powder was determined utilizing Micromeritics AccuPyc 1330 Gas 
pycnometer S/N-4011 (Norcross, GA). Prior to each run, calibration was performed. The 
sample was filled in 10-cm3 sample cup and the weight of the sample was noted. True 
density was measured at an equilibration rate of 0.0050 psig/min and the number of 
purges was set to 10. Bulk density was calculated by measuring the volume of a 5 g 
milled extrudate in a 10 ml graduated cylinder. Porosity was calculated by the following 
equation (Joshi, Das, & Mukherjee, 1993): 
 
 %𝑷𝒐𝒓𝒐𝒔𝒊𝒕𝒚 =  𝟏 − 
𝑩𝒖𝒍𝒌 𝑫𝒆𝒏𝒔𝒊𝒕𝒚
𝑻𝒓𝒖𝒆 𝑫𝒆𝒏𝒔𝒊𝒕𝒚
 𝑿 𝟏𝟎𝟎 
 
2.3.4. In-vitro buoyancy efficiency and dissolution studies 
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The buoyancy efficiency of mini-tablets in terms of lag time and the floating period 
was determined using the dissolution method. Dissolution studies were conducted on 
USP apparatus II (Hanson SR8) with 900 mL of medium 0.1N HCl, maintained at 37°C ± 
0.5°C with a paddle rotation speed of 50 rpm. Data were collected at 0.25, 0.50, 0.75, 
1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, and 6.00 h. All buoyancy tests 
were performed by visually checking the state of mini-tablets (buoyant, rotated or sunk) 
every 1 h up to 12 h and the end point of 24 hrs (Fukuda et al., 2006b). Lag time and 
floating period were determined in seconds and hours, respectively. In-vitro release 
studies (n = 3) analysis were performed according to USP using dissolution apparatus II 
(Hanson SR8), equipped with UV-Vis probes (Rainbow Dissolution Monitor, pION).  
 
2.4. Results and discussion 
2.4.1. Extrudates physical appearance and milling efficiency 
Extrudates were found to be intact for all formulations (Figure 2-2) except for the 
formulation containing 4% and 10% sodium bicarbonate, wherein deformations and dents 
in some portions of extrudates (non-intact extrudates) were observed. This was owing to 
thermal effect and the higher percentage of sodium bicarbonate present in the blend, 
which resulted in the excess CO2 release. This, in turn, affects the quality of extrudates for 
further processing, i.e. mini-tablet pelletization and a variation in the size of the mini 
tablets would occur. Milling efficiency was significantly enhanced in case of the 
formulations prepared by injecting P-CO2 gas (F2 and F5). Therefore, there is a decrease 
in milling time and increase in milling efficiency. 
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2.4.2. SEM investigations 
The SEM images as noticed in Figure 2-3 (a) of the formulation processed by 
conventional extrusion method (i.e. with neither P-CO2 nor incorporating sodium 
bicarbonate) clearly showed small open pores of approximately 66 µm in size. Since 
APAP is hygroscopic in nature, an evaporation process inside the barrel of extruder 
results in the formation of small-opened pores. Usually while processing the formulation 
at around 100 °C the water molecule droplets present in APAP will evaporate and 
converted into a gaseous state and in this rapid movement, it generates small pores. In 
contrast, when the only pure polymer is extruded (i.e. no hygroscopic API), no pores 
were observed as noticed in Figure 2-3 (f). In addition, the mini-tablets obtained using a 
P-CO2 approach contained many closed pores of approximately 200 µm in size, covered 
with a thin layer, as seen in Figure 2-3 (b). These covered pores with thin layer have the 
size of around 200 µm, but still these mini-tablets have more retarding release behavior, 
because they are less dense. Therefore, they are less immersed and part of them is 
exposed to the air on the surface of the media. In case of sodium bicarbonate formulation 
Figure 2-3 (c,d), they are all opened small oval pores, and the more retarding release is 
because they are less dense and more exposed to the air on the top of the media. 
Interestingly, as noticed in Figure 2-3 (e) the pores are larger than 200 µm in size and this 
explain the more floating period (168 h) in formulation 5 as described in Table 2-3. 
 
2.4.3. Density and porosity measurement 
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Porous extrudates were obtained with the aid of P-CO2, and these had a relatively 
lower density and higher porosity, than the formulations prepared using sodium 
bicarbonate and the conventional method and the data for porosity measurement are 
represented in Table 2-3. It has been concluded that the higher %porosity values are with 
the formulations prepared by P-CO2 (F2 and F5) in a reproducible manner among 
batches. However, the porosity was not reproducible with the formulations of sodium 
bicarbonate (F3 and F4), which appeared to be variable. These data are in a good 
agreement with buoyancy efficiency in these formulations. P-CO2 gas generates regular 
rounded and well-ordered pores and intact extrudate strands, whereas the extrudates 
prepared by incorporating sodium bicarbonate suffuse and liberate some carbon dioxide 
molecules, resulting in smaller, random, oval pores in some portions of extrudates and 
produce clumsy and non-intact extrudate strands. Thus, thermal decomposition of sodium 
bicarbonate inside the barrel results in liberation of CO2, water molecules, and anhydrous 
sodium carbonate in the softened polymer (Fukuda et al., 2006b). This might be a 
problematic issue in the term of formulation stability over a period of time. 
 
2.4.4. Buoyancy efficiency and dissolution profile 
As shown in Table 2-3, the lag time for the proposed approach (HME/P-CO2) is 0 
sec, compared with that of the traditional HME approach (approximately 2 min, P < 
0.05). The optimized formulation developed using a HME/P-CO2 approach had a floating 
period of around 54 h. Also, it had an efficient floating behavior with an optimal drug 
release pattern. Formulations containing sodium bicarbonate (F3 and F4) displayed a 
21 
 
more extended floating period owing to traces of CO2 in the manufactured mini-matrices. 
These traces are released gradually upon contact with gastric media, forming new pores 
that are neither filled nor saturated with gastric media, thereby extending the buoyancy of 
the preparations. The density of formulation F5 was low (data not shown) owing to the 
absence of API, resulting in a longer floating period than that observed for F3 and F4. 
Additionally, F5 did not disintegrate even after 7 days. In contrast, in the case of (F2), the 
saturated mini-matrices increased the weight of the mini tablets, until they eventually 
sank and disintegrated.  
      In-vitro release profiles of injected P-CO2 mini-tablets in acidic media have given the 
optimal sustained-release profile that meets USP-NF specifications after 3 h i.e. not less 
than 85% of APAP should be released. In this study, the in-vitro release profile of 
optimized formulation F2 was approximately 86.5%, in 3 h (Figure 2-4). Interestingly, F4 
gave the most retarding release behavior and this is because of the new born pores that 
formed when contacted to the media upon time through the traces of sodium bicarbonate 
that has not liberated the CO2 by thermal effect while extruding the blend. Therefore, less 
immersed in the media and most parts of mini tablets are exposed to the air. These data in 
a good agreement with extended buoyancy efficiency data in F4. In contrast, in F2, CO2 
might be entrapped in the closed pores, and the glassy, transparent thin layer covers the 
pores. These covered pores hold, embed and incorporate the API firmly. Therefore, the 
gradual release of API takes place upon contact with gastric media after swelling of this 
hydrophobic thin layer. Therefore, results demonstrate that this floating device is safe in 
regard of burst and faster or immediate release of the drug as throughout this device there 
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are relatively bigger large, rounded pores. Thus, generating relatively larger rounded 
pores (super porous) via P-CO2/HME technology. This approach provides a superior 
alternative for opening new trends for the manufacturing floating devices with the 
extended release profiles. 
 
2.5. Conclusion 
    In conclusion, the floating device formulated in this study by utilizing 
tasteless/odorless P-CO2 gas, in conjunction with HME technology, possesses optimal 
buoyancy. Using this combined technology, low-density floating devices can be easily 
designed and developed for other APIs/polymers. The combination of injecting P-CO2 
gas and continuous HME process overcomes the existing limitations commonly 
associated with other conventional techniques for manufacturing floating solid dosage 
forms. Moreover, the mini-tablets produced using this novel technology, possess superior 
buoyancy efficiency in terms of lag time and floating period. This study provides an 
important insight into combining HME/P-CO2 continuous technology for the 
development of FDDS, which may be useful for large-scale production of floating 

















FDDS prepared by hot-melt 
extrusion process with the aid of 
sodium bicarbonate 
• Patients on salt restriction diets or have 
congestive heart failure, kidney function 
impairment, and high blood pressure are 
on risk by chronic use of these 
formulations because of high sodium 
content. 
 
• Sodium bicarbonate by thermal effect 
while extruding in conventional extrusion 
process converts to CO2, sodium 
carbonate and water. Therefore, sodium 
carbonate and water might have an 
impact on drug stability or drug-excipient 







• Acid reflux and irritation of esophagus 
through esophagus sphincter can be 
caused by these gas-generating systems.  






FDDS that utilize effervescent 
system 
alkalizer and increase the 
microenviromental pH by 
microenvironmental pH modulation that 
causes some limitations in terms of 
dissolution aspects especially the APIs 
that dissolve in acidic media. 
• Gastric rupture caused by excess gas 
release (when combined with gastric 
acid).  
 
FDDS that utilize low density lipid 
 
• Stability and lipid polymorphism issues. 
 
Microsphere and gel rafting system 
 











Table 2-2: Formulation compositions 














N/A N/A 4 10 N/A N/A 
 










Table 2-3: Process parameters and floating properties 






























F2b 100 110 83-86 63.85 0 54 57.2 
F3 100 110 69-78 54.00 120 72 72.1 
F4 100 110 67-79 55.13 32 144 42.5 
F5b 100 165 82-86 66.50 0 168 N/A 
27 
 
F6 100 150 74-79 53.62 Sank N/A N/A 
 


















Figure 2-1: (a) Schematic representation of preparation of floating mini-tablets using 16-





     Figure 2-2: Digital picture of the extrudate strands 
     (a) F1: prepared using conventional HME process (control formulation), (b) F2:          
     prepared using HME process with P-CO2 injection, (c) F3: prepared using  
     conventional HME process with sodium bicarbonate (4%), (d) F4: prepared suing   
     conventional HME process with sodium bicarbonate (10%), (e) F5: HME process for  
     pure polymer (EUD) with P-CO2 injection and no sodium bicarbonate, (f) F6:   
     conventional HME process for pure polymer (EUD) with no P-CO2 injection or 




       
Figure 2-3: SEM images of mini tablets  
F1: prepared using conventional HME process (control formulation), F2: prepared using 
HME process with P-CO2 injection, F3: prepared using conventional HME process with 
sodium bicarbonate (4%), F4: prepared using conventional HME process with sodium 
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bicarbonate (10%), F5: HME process for pure polymer (EUD) with P-CO2 injection and 
no sodium bicarbonate, F6: conventional HME process for pure polymer (EUD) with no 
P-CO2 injection or sodium bicarbonate 
 
 
Figure 2-4: Drug release % in 0.1 N HCl 
F1: prepared using conventional HME process (control formulation), F2: prepared using 
HME process with P-CO2 injection, F3: prepared using conventional HME process with 










DEVELOPMENT AND CHARACTERIZATION OF SUSTAINED-RELEASED 
DONEPEZIL HYDROCHLORIDE WITH VARIOUS HYDROPHOBIC CARRIERS 
UTILIZING HOT MELT EXTRUSION TECHNOLOGY 
ABSTRACT 
 Manipulating the release profile for such a hydrophilic drug such as Donepezil 
Hydrochloride (DH) could be challenging. The precise and reproducible behavior of the 
release profile is often crucial to obtain the desired therapeutic outcomes. The aim of this 
work was to obtain release profile of hydrophilic drug from hot-melt extruded solid 
dispersion via rational screening of hydrophobic carriers that have features of pH 
independent swellable and low-permeable as in Eudragit® RS PO (E-RS) and pH 
independent non-swellable as in ethyl cellulose N7 (EC-N7), and lipidic compositions as 
in Compritol® 888 ATO (C-888) with or without pore-forming agent. DH, E-RS, EC-N7 
and C-888 was selected as the model drug and carrier excipients, respectively. Mannitol 
(MNT) was chosen as the temporary pore-forming agent. The thermal analysis showed 
that both drug and C-888 preserved their crystallinity within solid dispersion. Upon 
dissolution test, mannitol could generate pores and the drug release rate was 
proportionally correlated to the mannitol content. Tailoring the ratio of C-888 and MNT 
in the formulations, along with an appropriate extrusion temperature profile, resulted in 
modifying the release of DH and obtained the preferable release pattern. The burst release 
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issue relevant to other hydrophobic carriers could be problematic for patients where it 
might cause dose dumbing leading to initial sharp spike of DH levels in blood as in 
immediate release formulations. Therefore, C-888 has been chosen for further 
investigations to obtain tablets with high integrity. Optimized tablets were compared to 
the marketed formulation Aricept® in terms of release studies. Therein, the optimized 
formulation provided monophasic behavior of extended release profile close the release 
behavior of Aricept® with good tablets characteristics. It has been concluded that hot melt 
extrusion (HME) technique can be utilized for the manufacture of DH sustained release 
tablets with improve tablet integrity and characteristics by co processing of tablet 
excipient with DH/C-888. Tailoring the ratio of C888, tablet excipient and MNT in the 
formulations, along with an appropriate extrusion temperature profile, resulted in 
modifying the release of DH and obtained the preferable release pattern. 
 
3.1. Introduction 
    Donepezil Hydrochloride (DH) (melting point: 220-222°C) is a reversible inhibitor of 
acetylcholinesterase and has its effect by increasing the concentrations of acetylcholine 
and by enhancing cholinergic function in the brain. It is indicated for the treatment of 
mild to moderate dementia associated with Alzheimer’s (Rogers, Farlow, Doody, Mohs, 
& Friedhoff, 1998). DH’s aqueous solubility is ≥20 mg/mL. Therefore, it’s considered 
highly water soluble active pharmaceutical ingredient (API). Hydrophobic materials such 
as ethyl cellulose is used in pharmaceutical formulations as a carrier to extend the release 
of APIs over a prolonged period of time (Almeida et al., 2012). Ethyl cellulose (EC-N7) 
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is a cellulose ethyl ether, non-swellable, insoluble component. Another example is 
Eudragit® RS PO (E-RS) which is powdered cationic low permeable hydrophobic 
polymer. Lipid matrices such as Compritol® 888 ATO (glyceryl behenate USP-NF) (C-
888), usually used as a pH-independent sustained-release carrier and has a melting point 
of around 74 oC, (Hydrophile-Lipophile Balance (HLB) = 2). It has been extensively used 
previously to extend the release of water-soluble APIs. It might be highly effective even 
for highly water-soluble API due to its lipophilic nature and reduced wettability ( a 
Obaidat, 2001; Vithani et al., 2013a). C-888 is a hydrophobic carrier that incorporates 
API molecules in the tablet matrix and has specific uses in tablet compression, provides 
pH-independent drug release, has high resistance to physiological conditions due to its 
non-digestible nature, and has history of use in internationally approved and 
commercialized drug products ( a Obaidat, 2001). In this study, HME as a processing 
technology has been utilized to produce the sustained release formulations of DH. 
     
     HME is a common technology that can be applied to many pharmaceutical 
preparations especially to solid dispersions. Either raw materials alone or blends can be 
mixed and extruded under certain conditions as a feasible and continuous process. There 
are some parameters of HME that should be considered such as feeding rate, shearing 
force, temperature, die geometry, barrel design, screw rotating speed. With optimization 
these parameters, formulators can contribute in production of a desired final product with 
preferable drug release profile, uniformity of size, shape and content. HME offers some 
advantages over other conventional methods. For example, it is a one-step solvent-free 
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process, giving a continuous operation, scalable process which has fewer processing 
steps, requires no compression and can improve bioavailability due to dispersion of the 
drug at the molecular level in such a dosage form (Crowley et al., 2007; Michael a Repka 
et al., 2012; Shah, Maddineni, Lu, & Repka, 2013b). The growing demand for versatile 
continuous processes in pharmaceutical industry has made HME a preferable technique 
in their production lines. The reduction of waste, energy, and finally costs are advantages 
of continuous process as compared to a single batch process such as heat fusion process 
(melt and mix methods) (Li et al., 2006; Plumb, 2005; Yvonne Rosiaux, Jannin, Hughes, 
& Marchaud, 2014). Some of conventional methods like sintering techniques have been 
investigated (R. Singh, Poddar, & Chivate, 2007). Therefore, these techniques could 
mimic the residence time when we decrease the screw speed of extruder. HME is a 
continuous process version of batch process of sintering techniques. Few limitations that 
restrict the use of HME in the pharmaceutical industry are that it requires a higher energy 
input compared to other techniques and may exclude some thermo-labile compounds due 
to high processing temperatures. However, in the case of lipid matrices such as C-888, 
there is no need for this high-energy input since most of them have relatively lower 
melting point as compared to other hydrophobic carriers such as EC-N7 and E-RS. It is 
widely accepted that HME technology is an innovative and feasible approach in the 
preparation of various pharmaceutical drug delivery systems such as mini tablets, 
granules, immediate and modified release tablets, oral fast dissolving systems, and 
transdermal delivery systems. HME technology can also be used for taste masking of 
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bitter active substances by way of incorporating them in hydrophobic matrices (Crowley 
et al., 2007; Michael a Repka et al., 2012; Shah et al., 2013b). 
     
     Formulations factors that are based on different ratio of API/hydrophobic carriers and 
mixture of two hydrophobic carriers with the API with or without pore former e.g. 
mannitol (MNT) can play a critical role on the final product characteristics. It can be used 
to produce different extended release profiles (i.e. stable monophasic or diphasic release 
profile) as well as to produce different physicochemical characteristics for highly soluble 
drugs like DH. Controlling either formulation parameters (e.g. ratio of DH/carrier, and 
formulation composition) or processing parameters (e.g. processing temperature, screw 
speed) could play a significant role on the behavior of the drug release profile as well as 
physicochemical properties of the DH within the matrix. The effect of the processing 
temperatures, formulation composition, the impact of the fillers on drug content, tablet 
disintegration, DH/carrier ratio and compression force have not been investigated yet. In 
a previous study, the influence of some of these parameters on a different API (diclofenac 
sodium) release behavior has been studied (Vithani et al., 2014, 2013a).  
 
     Lipid aging could lead to instability during storage. It is the main disadvantage when 
using lipids in pharmaceutical formulations as their physical properties could change 
during storage. One of these effects for example is an increase of melting ranges, melting 
enthalpy, pore formation on the surface, rheological changes, and a decrease in tensile 
strength (Reitz & Kleinebudde, 2007).  
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     In this study, HME has been utilized to prepare solid dispersions of DH in C-888 
matrix and in other hydrophobic matrices, which are EC-N7 and E-RS in order to 
produce a more desirable release profile. In the case of lipid matrix of C-888, we have 
compared the results obtained from this process via HME with the results of conventional 
process such as “hot fusion method” (Li et al., 2006) in order to observe how efficient 
HME on manufacturing a desired final product. The main objectives of this study were to 
develop and evaluate sustained-release DH formulations using hydrophobic carriers such 
as C-888, EC-N7 and E-RS utilizing HME technology and thereby avoid the side effects 
(nightmare, insomnia, anxiety, nausea, emesis and/or diarrhea) associated with initial 
sharp spike in blood DH levels for immediate release formulations. Formulations that 
provide immediate release of DH are administered once a day. However, the peak plasma 
concentrations are reached in 2 to 5 hours, resulting in initial sharp spike in blood plasma 
levels (Fanda, Singh, & Vivek, 2011). This sharp spike could cause undesirable 
cholinergic side effects as mentioned above (Rogers et al., 1998), (Fanda et al., 2011). 
Furthermore, the specific aims of this study were to study the effect of the extrusion 
temperature on the drug physical state and drug release profiles from lipid carrier and 
compare it to conventional-processed formulation. In addition, improvising drug content 
and content uniformity for lipid-based tablets prepared via HME. The extrusion of pre-
mixed tablet excipients (i.e. microcrystalline cellulose (MCC), and MNT) is considered 
as a critical aspect in this study. Co processing tablet excipients is expected to be cost 
effective process since there are fewer manufacturing steps. For instance, tablet’s 
excipients blending step. However, it is mandatory to investigate the effect of the added 
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excipients on tablet’s physico mechanical properties (e.g. drug content and tablet content 
uniformity, hardness, friability, dissolution profile). To the best of our knowledge, there 
is no published work has been done on DH via HME. 
 
3.2. Materials 
    DH USP was purchased from Wuhan Hengheda Pharm Co. (Wuhan, China). C-888 
was kindly received by Gattefossé (Saint-Priest, France). EC-N7 was obtained from 
Ashland (Ashland Aqualon Functional Ingredients, Wilmington, DE, USA). E-RS were 
kindly gifted by Evonik (Piscataway, USA) and Avicel® PH 102 (MCC) has been 
received from FMC Biopolymers (1735 Market Street, Philadelphia, PA 19103). 
Magnesium stearate were purchased from Spectrum Chemicals (Gardena, CA). Pearlitol® 
(MNT) was received as a gift sample from Roquette America Inc. (Keokuk, IA, USA). 
Stearic acid was purchased from Mallinckrodt Chemical Ltd. (Bedminster Township, NJ, 
USA). Marketed Aricept® tablets were purchased from local university pharmacy 
(Oxford, MS, USA). All chemicals and solvents utilized for analysis in the study were of 




3.3.1. Thermogravimetric analysis (TGA) and differential scanning calorimetry 
(DSC) 
    The thermal stability of DH and the carriers at the employed processing temperatures 
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was determined by Thermogravimetric analysis (TGA, Pyris 1 TGA Perkin Elmer). A 
Perkin Elmer Pyris 1 TGA running Pyris manager software (PerkinElmer Life and 
Analytical Sciences, 719 Bridgeport Ave., Connecticut, USA) was utilized to do 
thermogravimetric analysis of samples. Drug and its excipients were evaluated for 
thermal stability at high temperatures. Three to four milligrams of the sample were 
weighed and heated from 25°C to 250°C at 10°C/min heating rate under an atmosphere 
of nitrogen (data not shown). Differential scanning calorimetry (DSC, Diamond DSC, 
Perkin Elmer) was utilized to determine the physical state of different API/carrier ratios 
in each physical mixture and extrudate (EXT). The physical state of pure drug, pure 
carrier, physical mixtures and EXTs was studied. The heating range used was from 30 0C 
to 250 0C at a heating rate of 20 0C /min under nitrogen (N2) atmosphere. Due to the low 
melting point of lipid, it was heated from 30 0C to 100 0C at the same scanning rate. 
Sample prepared weighing with an approximate initial weight of 4–5 mg in a sealed 
aluminum pan. Certain software has been utilized to calculate the endothermic onset and 
peak temperatures at melting. The name of software is Pyris manager software (Shelton, 
CT, USA). It was used to analyze the data generated to evaluate crystallinity. The DSC 
was calibrated initially with an Indium reference. In addition, the drug/lipid miscibility 
was estimated using Hoftyzer and Krevelen approaches and the Hansen solubility 
parameters (Hansen, 1969). 
 
3.3.2. Solubility parameter calculation for optimized formulation  
       Solubility/miscibility is an important parameter in solid dispersion formulations. 
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Hansen solubility parameters can be obtained from the literature. However, it can be 
calculated through Molecular Modeling Pro, v6.2.8 (ChemSW, Fairfield, CA, USA). This 
software can be used conveniently to calculate the solubility parameters for certain 
pharmaceutical materials via implementing their corresponding melting points and 
molecular structures.  
 
3.3.3. HME processing method 
       For screening purposes, three different carriers, C-888, EC-N7 and E-RS have been 
used (alone or in combination) at different ratio and processing parameters (Table 3-1, 3-
2, 3-3) to evaluate their effect on sustaining the DH release. Materials were blended using 
a V-shell blender (GlobePharma, Maxiblend®) with and without mannitol as a pore 
former and samples analyzed for drug content and content uniformity. Prior to HME, 
materials were sieved using USP mesh size #35 to remove any aggregated and 
agglomerated particles. The blended materials were extruded on a 16 mm Prism Eurolab, 
ThermoFisher Scientific Co, rotating twin-screw extruder utilizing a round-shaped die to 
produce rods EXT. In addition, to study the effect of processing temperature on lipid, the 
materials ran through the heated barrel with screws rotating speed of at 50 rpm and 
the temperature for all zones of the extruder was set at 70 or 75 or 77 °C except for the 
last  zones and the die which were set at 70 °C to make EXTs cooled down and solidified 
(Table 3-4).  The reason why different temperatures have been set is to see the effect of 
temperature degree on drug and lipid crystallinity and the drug release profile. The 
processing temperature profile and screw speed were based upon the physical properties 
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of hydrophobic carriers in the preliminary studies. Resulting EXTs were further 
processed using a comminuting mill (Fitzpatrick, Model “L1A”) and then sieved using 
USP mesh size #35.  
      Another part of this study is to improve the drug content and content uniformity of 
the optimized formulation from screening stage based on drug release profile which is 
(DH:Lipid). As shown in (Table 3-5, 3-6), DH (33.3 - 50% w/w) (1:2, 1:1 ratio) and C-
888 were blended and extruded as the same procedure and processing conditions as 
previously mentioned during the screening stage but with and without premixed MCC as 
a tablet diluent while extruding the blend to observe the effect of pre-mixed MCC on 
drug content and content uniformity as well as release profile.  
 
3.3.4. Conventional heat fusion processing method 
    It’s also called melt and mix. This method only used for C-888 to compare its 
performance with the formulation from HME. In this processing method, C-888 has been 
melted in porcelain casseroles at 100 °C until a homogeneous melt was obtained, then 
DH has been added and mixed manually to the homogenous melt. The mixture was kept 
to gradually cool down with continuous stirring until the congealed mass was obtained. 
Then the mass melt was milled using the same milling method as mentioned before in 
HME processed formulations. Subsequently, the mass was ground, pulverized and passed 
through a then sieved using USP mesh size #35. All processed powders were stored in a 
desiccator at room temperature until further use is needed. 
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3.3.5. Physico mechanical evaluation for milled EXTs properties for optimized lipid 
formulation 
    Bulk and tapped density was calculated by measuring the volume of a 5 g milled EXTs 
in a 10 mL graduated cylinder(B. K. Almutairy et al., 2016). Firstly, the initial occupied 
bulk volume in the cylinder was noted. Secondly, after tapping the cylinder 100 times, 
the tap volume was noted. The bulk density (𝜌 𝑏𝑢𝑙𝑘) and tap density (𝜌 𝑡𝑎𝑝) were 
calculated by dividing the weight of milled EXTs over the respective volume. Using 
following equation (Eq. 1), the Carr’s compressibility index (CI) was calculated: 
 𝐶𝐼 =  (
𝜌 𝑡𝑎𝑝−𝜌 𝑏𝑢𝑙𝑘
𝜌 𝑡𝑎𝑝
) 𝑥 100   ---- Eq. 1 
Hausner ratio (HR) was obtained by dividing (𝜌 𝑡𝑎𝑝) over (𝜌 𝑏𝑢𝑙𝑘).  
 
3.3.6. Tablet processing 
    The milled EXTs were mixed with tableting excipients (MCC and magnesium stearate) 
(Table 3-5, 3-6) and compressed into tablet equivalent to 23 mg of DH with compaction 
force of 600 and 1500 psi. Tablets were compressed on a manual tablet press using 10 
mm round concave punch to a final tablet weight of 300 mg. The tablets, having 
luminous surfaces, were stored in a plastic bottle until further use. Tablets were evaluated 
for thickness, hardness, friability, and in-vitro release profiles. In addition, drug content 
and tablet content uniformity tests have been conducted. DH content has been analyzed 
using a Waters HPLC-UV system (n=3) (Waters Corp, Milford, MA). For improving 
drug content, the pre-mixed MCC formulations were compressed on single punch tablet 
press (MCTMI, Globe pharma), using 8 mm round flat punch with compaction force of 
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1500 psi. Magnesium stearate (1%) was added as a lubricant just before the direct 
compression process, and each compressed tablet weighed 200 mg to mimic the weight 
of Aricept® which is the commercial product of DH that has been used in this study as a 
control formulation. 
 
3.3.7. Tablet characterization 
     Some standard characterization tests were achieved on tablets manufactured from 
extruded materials. The thickness and diameter of the tablets was measured using a 
micrometer. Disintegration testing was performed via disintegration apparatus. Friability 
testing was performed in a friabilator (Roche friabilator). To test the hardness of tablets, 
A VarianVK200 (Agilent technologies, 13000 Weston Pkwy, Cary, NC, 27522) hardness 
tester was used. Tablet content uniformity test was achieved by drug assay via HPLC 
method. Tablet weight uniformity test was performed via measuring each tablet after 
direct compression via Mettler Toledo scale. Six replicates were tested (n=6). 
 
3.3.8. In-vitro release studies 
     In-vitro release studies for either milled EXTs or tablet equivalent to 23 mg DH were 
performed using a USP Type-II dissolution apparatus with 900 mL of pH 6.8 phosphate 
buffer at 37±0.5 0C at 50 rpm for 10 hours (Azarmi, Roa, & Löbenberg, 2007; 
“Dissolution Methods,” 2014). All dissolution samples were analyzed using a Waters 
HPLC-UV system (n=3) (Waters Corp, Milford, MA). Paddle speed was set at 50 rpm. 
Samples were collected at every 0.5, 1, 2, 3, 5, 8 and 10 h, filtered and then analyzed 
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using an HPLC. We compensate the withdrawn amount for sample with an equal amount 
of fresh dissolution media by adding back to the dissolution vessel at each time point. We 
plot the release profile for percent release to time. Model independent similarity factor 𝑓2 
has been used to compare among dissolution profiles. Furthermore, statistical analysis 
was conducted using ANOVA to compare the profiles. Based on FDA guidelines, it’s 
well known that if the calculated  𝑓2 is between 50-100, then the profiles are considered 
to be similar (“Guidance for Industry. Dissolution testing of immediate release solid oral 
dosage forms,” 1997). 
 
3.3.9. HPLC method  
    An in-house reverse-phase HPLC-based analytical method was developed for the 
determination and quantification of DH. This method was validated according to a 
previous research group (Pappa, Farrú, Vilanova, Palacios, & Pizzorno, 2002).  The 
HPLC equipped with a UV detector, Waters Symmetry shield 5μ C18 column (250 x 4.6 
mm) and an isocratic mode of elution. The mobile phase was a mixture of methanol, 0.02 
M buffer phosphate and trimethylamine (50:50:0.5). Buffer phosphate was prepared by 
dissolving 2.4 g of monobasic sodium phosphate in 900 ml of water, mixing with 10 ml 
of trimethylamine and adjusting to pH 2.7 ± 0.5 with phosphoric acid. The mobile phase 
was filtered through a nylon membrane (pore size 0.45 µm) and degassed before use. 
Chromatography was performed at room temperature using a 1.0 ml/min flow rate and a 
15 min run time. In these conditions, DH retention time (tR) was roughly 9 min. The 
injection volume was 20 µL and ultraviolet detection was at a wavelength (λmax) of 268 
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nm (2 aufs). The column temperature was 40 °C.  Finally, the acquired data were 
processed using Empower 2 build 2154 software (Waters Inc., Mount Holly, NJ, USA).  
 
3.3.10. Scanning electron microscopy (SEM) 
    Surface morphology of the pure drug and milled EXTs was studied by SEM. Samples 
were mounted on adhesive carbon pads placed on aluminum stubs. Gold was used to coat 
the samples by a Hummer® 6.2 sputtering system (Anatech LTD, Springfield, VA) in a 
high vacuum evaporator. A scanning electron microscope operating at an accelerating 
voltage of 0.8 kV was used for imaging (JEOL JSM-5600). The morphology of 
formulations might reflect the crystallinity status of the DH.  
 
3.3.11. Statistical analysis 
    The data were expressed as the mean ± standard deviation (SD). The confidence 
interval was chosen to be 95% and a statistically significant difference was determined at 
a minimal level of significance of 0.05 using Student’s t-test. 
 
3.4. Results and discussion 
3.4.1. TGA 
    Prior to HME, we could determine the maximum processing temperatures by utilizing 
TGA. This analysis indicates thermal stability for APIs and excipients/carriers being 
processed via HME by determining the amount of weight loss due to decomposition as a 
function of temperature. In present study, it has been found that less than 2% degradation 
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below 250 0C for the neat martials, physical mixtures and EXTs at various drug: carriers’ 
ratio and different temperatures profiles (data not shown). TGA confirmed the thermal 
stability of API and excipients/carriers at extrusion temperature utilized during 
processing as well as provide a working temperature range. Therefore, as a crucial aspect, 
it has been concluded in our study that the processing temperatures studied were 
convenient to employ during the extrusion process. 
 
3.4.2. DSC 
    The solid dispersion EXTs were characterized via a thermal and diffraction techniques 
such as differential scanning calorimetry (DSC) to determine the API state within 
hydrophobic matrix.  Physical state of DH was found to be either crystalline or 
amorphous depending on carrier used and processing conditions. In this study, DSC was 
utilized to characterize the physicochemical properties as physical mixture (PM), solid 
dispersions (EXT) and as individual neat components. Since change in 
crystallinity/amorphousity or change from one polymorph to another often exhibit 
significant differences in solubility, bioavailability, processability and physical/chemical 
stability, these thermal studies have been achieved to evaluate the effect of processing on 
the crystallinity of the DH and lipid. As we can see in DSC graph (Figure 3-1,3-2,3-3,3-
4), neat DH has two characteristic melting endothermic peaks at around 145 0C and 228 
0C (Subedi, Ryoo, Moon, Chun, & Choi, 2012). In addition, lipid has a characteristic 
melting endothermic peak at around 74 0C. For all EXTs, the first melting endothermic 
peak completely disappeared. The EXTs containing E-RS as a hydrophobic carrier or 
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MNT as a pore former did not exhibit melting endotherms, indicating that DH rendered 
amorphous during the extrusion process which is not preferable in our study since the DH 
is already highly soluble drug. The melting endotherm for lipid was apparent in all EXTs 
but less intense (i.e. less delta H “enthalpy”) compared to the pure lipid and physical 
mixture indicating that the extent of crystallinity of the lipid was greatly reduced. This 
means that extrusion process has an effect on lipid crystallinity and this is beyond the 
scope of this study. Lipid endothermic melting peaks were slightly shifted to around 70 
0C for all drug loadings indicating negligible drug–lipid interactions. Regarding the 
formulation that has mixture of EC-N7 and lipid (1:1) containing DH, it was indicated 
that the lipid was dispersed within the EC-N7. The reduced melting endotherm of lipid in 
EC-N7:lipid formulation impart that a fraction of the lipid material recrystallizes as a 
separate phase before EC-N7 vitrified (solidified)(J. M. Keen et al., 2015). This 
crystalline phase of lipid was observed in DSC graphs. These findings mean that in some 
formulations DH has partial crystallization within the carrier matrix and has not 
converted completely to higher energy amorphous form. This amorphous is not 
preferable in our study because of the risk of related stability issues if there is any. Such 
an issue that consequently affecting the relevant dissolution profile and other 
physicochemical aspect.  
 
3.4.3. Solubility parameter calculation for optimized formulation 
    A three-dimensional Hansen solubility parameter impart information about physical 
state and interactions such as dispersive, polar, and hydrogen bonding interactions of a 
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molecule, and it could be used to characterize the interactions between formulation’s 
compositions(Hancock, York, & Rowe, 1997). It is a very useful tool in pharmaceutical 
applications. It could predict the API morphology, drug–carrier miscibility in the solid 
dispersions, and the drug–excipient interactions in the field of pharmaceutical 
development. The effective solubility parameter obtained from Hansen method for DH 
and lipid were 28.3 and 19.6 MPa1/2, respectively. Theoretically, in order to observe at 
least partial miscibility between the drug and the carrier, the solubility parameter 
difference () between them is required to be less than 7.0 MPa1/2 (Forster, Hempenstall, 
Tucker, & Rades, 2001; Greenhalgh, Williams, Timmins, & York, 1999). In the present 
study, ()  is 8.7, which is significantly more than 7.0 MPa1/2, indicating of 
immiscibility of DH in Lipid.  
 
3.4.4. HME processing method and carriers screening studies 
    The formulation with lipid was extrudable at the lowest processing temperatures (68-
74 °C) (Table 3-1), whereas in the case of E-RS, it was processed at a relatively higher 
temperature (150 °C) as described in Table 3-3. A combination of DH with a mixture of 
lipid and EC-N7 (1:1:1) has a significant effect to process the blend with relatively lower 
processing temperature (100 oC) compared to DH with EC-N7 (140 oC) as described in 
Table 3-2. Stearic acid has been utilized as processing aid. The formulation was 
compressed and densified in metering section and die. 
     In our preliminary study, we processed some batches by feeding manually, we 
noticed that when we stop feeding there is more residence time and less pushing 
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force caused by solid lipid material. This cause lipid to be melted and decrease the 
output product and increase the processing time. To identify a suitable carrier matrix 
to produce an ideal stable release profile that conforms with USP specifications and 
mimic the marketed formulation (Aricept®), different carriers such as EC-N7 and E-
RS and C-888 were evaluated for extrudability and desired release profiles.               
     Optimized HME processing conditions for carriers’ screening is shown in Table 
3-1, 3-2, 3-3. According to release profile in terms of stable monophasic sustained 
release profile, we found out that lipid is the most appropriate drug release profiles. It 
gave us nearly ideal zero order release profile. It doesn’t have burst release as other 
carriers. When using EC-N7 and E-RS as a matrix forming, during dissolution within 
first hours, DH release behave a faster release and this not preferable and could give 
a spike plasma drug level. Lipid was picked for further investigations since it doesn’t 
give initial burst release and retain crystallinity of DH. In addition, in HME process, 
there is DH transformation into partial or total metastable amorphous form of DH as 
in case of E-RS. It might recrystallize during storage and as a consequence, it would 
affect the dissolution profile afterward which is our goal in this study to keep a stable 
sustained release profile. To make sure that we preserve the drug crystallinity, we 
prefer to process at the lowest processing condition. Lipid can be used as a 
processing aid (J. Keen, Hughey, Bennett, Jannin, & W. McGinity, 2011) and it’s 
alternative to chemical plasticizer. Lipid did not undergo to any chemical 
degradation such as acid hydrolysis when extruding at higher temperature (Y 
Rosiaux, Girard, Desvignes, Miolane, & Marchaud, 2014b). In case of extruding the 
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lipid at higher screw speed, because of friction of screw to the lipid material 
generates extra source of heat, lipid starts to be liquefied so that we chose 50 rpm 
screw speed as the optimized speed instead 100 rpm. Lower than 50 rpm speed 
causes more residence time and the lipid gets liquefied as well and there a risk 
degradation of API because of longer residence time is attained. In case of lipid, 
when we extrude above the melting point, the resulting material is in liquid form. 
However, when extruding at away less than melting point of the lipid, it would give a 
granular/powdery solid rod EXTs. Extruding with EC-N7 and E-RS at the set 
temperature gave opaque solid rod EXTs. C-888, owing to its thermostable nature, 
have been utilized to form HME matrices. C-888 melts around 74°C and have been 
extruded below its melting point at around 70 °C (Michalk, Kanikanti, Hamann, & 
Kleinebudde, 2008; Y Rosiaux, Girard, Desvignes, Miolane, & Marchaud, 2014a; 
Vithani et al., 2013b; Windbergs, Strachan, & Kleinebudde, 2009). There are several 
advantages of using them as a processing aid instead of chemical plasticizers along 
with other hydrophobic polymers. One of these advantages is lower processing 
torque can be attained compared to EC-N7 and E-RS alone due to lower melting 
point of C-888. When used C-888 as a processing aid, the processing temperature 
significantly decrease to (100 °C) for EC-N7 polymer.  Barrel temperature and screw 
speeds of hot melt extruder were optimized for maximum yield and were set 
according to observations made from thermal studies and final EXT. Therefore, all 
three-hydrophobic forming matrix with DH showed excellent extrudability under the 
utilized processing parameters. Blends of the lipid and hydrophobic polymers can be 
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extruded and result in improved physico-mechanical properties; however, the process 
needs further optimization in terms of dissolution profiles, which is the subject of 
future studies. 
 
3.4.5. Tablet’s excipient MCC co-processed with lipid to improve tablet integrity 
    Co extrusion of premixed tablet excipients is a critical aspect in pharmaceutical 
industry and it has not been completely addressed yet. One of the major challenges while 
extruding lipids is that they have poor followability within the extruder barrel. This 
caused a drug content and content uniformity variation in this project. For optimized lipid 
formulation beside EC-N7 and E-RS. C-888-DH-MCC interaction, DH crystallinity, 
dissolution behavior, tablet integrity, lipid aging /API stability studies are critical aspects 
in this project which is a theme of a future study. Lipid can be extruded with tablet 
excipients such as dibasic calcium phosphate anhydrous (DCPA) (Vithani et al., 2014, 
2013b). To the best of our knowledge, MCC is the first time to extrude as a tablet’s 
excipient. Tablet’s excipients co processing is assumed to reduce processing steps (i.e. 
blending of tablet excipients), labor work and manufacturing time. Therefore, premixed 
tablet robustness in terms of drug content, tablet content uniformity, hardness, friability, 
and dissolution profile were investigated in our study. Tablet compositions are shown in 
Table 3-5, 3-6.  The extruding temperatures zones for the premixed MCC formulations 
was optimized and set to get the continuous and neat rod EXTs (Figure 3-5) at 
temperatures above C-888 melting point for the optimized formulations for further 
investigations. MCC was added to lipid matrix because of poor cohesive forces between 
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lipid particles since lipid is extremely hydrophobic in nature (Vithani et al., 2014). 
Therefore, co processing premixed MCC approach has been utilized to improve tablet 
integrity. Torque for the premixed MCC formulations compared to DH with lipid alone 
was higher. The reason is because more solid-state particles of DH and MCC. MCC has 
high melting point at around 270 ºC then it increased the resistance of the barrel because 
of frication forces leading to higher torque. For the optimized formulation after screening 
stage, when processing MCC for conventional tablet preparations, solid bridges by 
mechanical force via direct compression can occur. The MCC is not completely impeded 
within matrix tablet. However, interconnection bond after melting lipid (DiNunzio, 
Martin, & Zhang, 2010; Nyström, Alderborn, Duberg, & Karehill, 1993; F. Zhang, 2016) 
and intragranular and intergranular bonds with lipid while extruding the blends might 
occur (Y.-E. Zhang & Schwartz, 2003). Therefore, it can be concluded that this fusion 
bonding of MCC with lipid while extruding, made MCC completely embedded within the 
matrix and prevent tablet splitting and burst release in dissolution media instead of 
complete disintegration which was after 2 hrs in our case when MCC is not co processed 
via HME with the rest of formulation components. For the formulation 300 mg tablet of 
DH with lipid, the separation of tablet into parts was the main issue after contact with 
dissolution media after 15 minutes (i.e. cracking, capping) leading to faster release and 
complete release within 5 hrs. Therefore, we propose to co-extrude tablet excipient MCC 
to observe the effect on tablet integrity. The measured hardness with co extruded material 
was independent to the compaction force although the co extruded formulation is mixed 
with filler (i.e. MCC). However, with conventional methods of adding tablet excipient, 
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hardness was dependent on the compaction force. This can be explained as the MCC 
being embedded deeply within the matrix in case of premixed formulations whereas in 
the conventional formulation, MCC particles surround the solid dispersion particles of 
DH and lipid. The friability was less 1% that indicating lipid matrix tablet robustness. 
The EXT granules showed good CI which was between 15% to 16%. The less carr’s 
compressibility index is because of hydrophobic nature of lipids. After co extrusion with 
these kinds of fillers, there is no capping no lamination when contact to dissolution 
media. In addition, no lipid melting, egress, spread during tablet compression which is 
what we faced with conventional tablet processing in case of high ratio of lipid. These 
findings are in agreement with a previous study (Y.-E. Zhang & Schwartz, 2000). The 
formulations with C-888 along with MCC were extrudable at the lowest processing 
temperatures (70-75°C) but the strands were defected (Figure 3-5 b). However, they were 
harder and neater at higher temperature 77 °C (Figure 3-5 c) compared to DH: lipid 
(Figure 3-5 a) which were difficult to handle. These harder strands will be beneficial in 
downstream processing. The tablet formulation consisting of formulation DH: Lipid: 
Mannitol (1:2:0.075) milled EXTs demonstrated an average tablet hardness of 10 kp and 
thickness of 4.24 mm. The tablets were less than 0.1% friable but faster release and 
capping issue in dissolution media. Therefore, we utilize the co extrusion of tablet 
excipients. The premixed formulation milled EXTs tablets demonstrated an average 
tablet hardness of 6.8 kp and thickness of 3.2 mm. In addition, the friability was less than 
1%. The reason why the hardness is decreased is because as a result of decreasing the 
tablet weight (i.e. to 200 mg to mimic the marketed formulation), the amount of MCC 
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would be decreased. MCC has been reported to increase tablet strength in a certain 
amount and ratio.  Hausner ratio is for the premixed formulation was 1.13 which indicate 
good flow properties. 
 
3.4.6. Heat fusion processing method 
    The objectives of this study are to investigate the influence of traditional heat fusion 
processing techniques on lipid-based formulations and compare them to those prepared 
by HME processing techniques. The fusion method produces granules from congealed 
mass. This congealed mass has been reported to decrease the drug release behavior 
compared with traditional direct compression and wet granulation method. The efficient 
and intense mixing while extruding the material inside the barrel can incorporate more 
API particles within the lipid matrix and make the formulation with a more slower release 
behavior compared to heat fusion (data not shown).  The reason might be because the 
pore architecture is different in case of formulation prepared by continuous HME. It has 
less porosity compared to formulation prepared by batch process heat fusion. HME 
process gave us stable and slower release compare to heat fusion. Formulations prepared 
by heat fusion gave burst release. Our results in agreement with previous research group 
(A. A. Obaidat & Obaidat, 2001). Stirring force is not as efficient as shearing force by 
HME where DH can be completely embedded within the matrix as the same behavior in 
tramadol HCL prepared by heat fusion method that gave burst release while in our case 




3.4.7. Drug content and content uniformity 
    The conventional processed tablets have drug content and content uniformity variation 
because inefficient drag flow inside the barrel, due to the low melt viscosity of lipid. This 
makes the extrusion of the lipids a challenging process (J. Liu et al., 2001). Drug content 
and tablet content uniformity were improved on extruding the formulation with MCC 
(Figure 3-10). Drug content and tablet content uniformity analysis displayed that the drug 
was uniformly distributed within the tablets with a standard deviation of <4%, indicating 
a good formulation and process. The reason behind the improvements of drug content and 
content uniformity is that the MCC plays a vital role in improving lipid followability as it 
enhanced the drag flow and consistency of mixing inside the extruder barrel. Therefore, 
there was a good dispersive and distributive effect of DH particles inside the lipid matrix. 
The premixed MCC formulation exhibited a 102.4% drug content compared to those 
without MCC, which was approximately 71.4%. (P value equals 0.0003, statistical 
analysis using an unpaired t-test). 
 
3.4.8. Mechanism of MCC behavior on drug release from tablet prepared by 
conventional tableting method (i.e. not co processed MCC formulation) 
    MCC absorbed water into the tablet through capillaries, leading to swelling and 
eventual disintegration of the tablets. New surfaces were thus created for drug diffusion 
to occur. This finding is in agreement with El- Shanawany who reported a faster release 




3.4.9. In-vitro release study for the screened milled extrudates formulations 
    Lipid gave lubrication effect to EC N7 to decrease the processing temperature but 
didn’t solve the burst release behavior of EC-N7. As shown in Figure 3-9, Formulation 
(DH: Lipid: Mannitol 1:2:0.075) demonstrated sustained, stable and complete release in 
10 hours. Dissolution test showed various release profiles as seen in Figure 3-7 
(monophasic, biphasic release profiles) according to different carrier’s characteristics. 
The addition of MNT enhanced the drug release due to its pore forming capability. Using 
only a lipid as a carrier in the formulation resulted in a nearly ideal (zero-order) release 
profile; however, the physical properties of the extruded material were not suitable for 
further processing, such as tableting or capsule filling operations (i.e. in our case sticking 
in capsules and tablet separation and capping while in dissolution and then result in a 
faster and burst release). Film coating technique is the conventional solution to prevent 
burst release, but in case of lipid, there is no need to do this technique. Burst release 
phenomena could be solved by film coating but in our case, we solved the burst release 
with HME lipid extrusion. Initial burst release from the matrix could probably be 
attributed to the dissolution of drug from the surface of milled EXTs. This issue can be 
solved via HME but only in the case of lipid not E-RS, nor EC-N7. The goal of adding 
lipid in screening of polymers to decrease the extent initial burst release with other 
formulations as shown in Figure 3-7. Also, to avoid dose dumping caused by food 
agitation with other gel forming matrices (A. A. Obaidat & Obaidat, 2001; S. B. Tiwari, 
Murthy, Raveendra Pai, Mehta, & Chowdary, 2003). The reason why E-RS provided 
more sustained release because it is non-permeable polymer. Furthermore, the reason 
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why excluding E-RS and EC-N7 because it is not consistent release profile (diphasic 
release profile not monophasic release profile) and gave burst release during the first hrs. 
In the last hrs., the release profile only increased slightly because it is below the 
percolation threshed (Crowley et al., 2004) leading to incomplete drug release. This 
phenomenon usually happens assumingly due to limited access of deeper drug particles to 
the dissolution media since they are completely embedded in the hydrophobic EC-N7 and 
E-RS. During the initial stage of the dissolution test, drug clusters located on the surface 
of the granules were readily released into the dissolution medium. As the dissolution 
process progressed, fewer drug clusters were accessible to the dissolution medium and a 
plateau was reached (F. Zhang, 2016). This plateau behavior is because that it is under 
the percolation threshold. Below the percolation threshold, incomplete drug release is 
observed presumably due to limited accessibility of many drug particles to the dissolution 
medium since they are encapsulated by water insoluble polymeric materials (Crowley et 
al., 2004; F. Zhang, 2016).  
 
3.4.10. Effect of varying processing temperature and lipid ratio on dissolution 
profile of milled EXTs 
    The effect of extrusion temperature and C-888 ratio on release profile has been studied. 
It has been confirmed in previous studies that the processing temperature played a 
significant role in tortuosity of the carrier (Crowley et al., 2004; Frenning, 2011; J., P., & 
I., 2006; Y.-E. Zhang & Schwartz, 2003).  At processing temperature of the melting point 
of the lipid and above (i.e. 74 ºC and above), formulations processed via HME did not 
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give any fast release because of particles being on surface at the beginning which means 
that because of shearing force and mixing and distributive and dispersive mixing player a 
role in completely embedding the DH particles within the lipid matrix (Figure 3-8).  
 
3.4.11. Dissolution studies of processed tablets 
    MCC works by swelling in water, and eventually, disintegration of the matrix like 
what happened in conventional tablets. The release from all the tablets prepared was 
studied under different pH values. It was observed that the release of DH from such 
matrices is independent of the pH since the release rates were almost similar under the 
studied pH values. This result was expected since DH is a salt of a basic drug with a pKa 
of 8.2. Therefore, it is ionized over the pH range of interest and soluble at all pH values 
used in this study, and it can be concluded that the matrix is inert towards changes in pH. 
Presence of MCC which is hydrophilic polymer is not preferable for water soluble API, 
but this could be solved by premixed co extrusion. Faster and less consistent release was 
achieved from the conventionally prepared tablets comprising MCC and the structures 
were observed to swell and split into layers laterally during dissolution testing, which was 
ascribed to the nature of MCC promoting disintegration (Treanor, Roberts, Mostafa, & 
Miolane, 2010). The addition of MNT enhanced the drug release due to its pore forming 
capability. Formulation (DH: Lipid: Mannitol 1:2:0.075) demonstrated sustained, stable 




The premixed MCC formulation containing a mixture of DH, C- 888 ATO (1:2) and 
microcrystalline cellulose, exhibited a more sustained drug release as compared to the 
marketed Aricept® formulation. However, on increasing the drug ratio to (1:1), the drug 
release is enhanced and reached up to 81% after 10 hrs. (Figure 3-11) compared to 
control tablets (100% after 10 hrs). After 10 hrs in dissolution media, the premixed MCC 
tablets remained intact with no cracks and this explains the lower drug release profile 
compared to the marketed Aricept®. However, the conventional processed tablets 
demonstrated cracks in the middle of tablets. This explains the faster release profile. 
However, in the formulation of MNT (0.1), there is a burst release. The commercial 
control utilized a film coating technique to achieve extended release behavior. f2-




3.4.12. SEM analysis for carriers’ screening 
    Surface morphology was examined by SEM for all EXTs. As it can be seen in Figure 
3-6, the pure drug crystals appeared to be irregular in shape and size as aggregates of 
needle form i.e. microcrystalline aggregates with a coarse surface. DH: Lipid (1:2), DH: 
Lipid: EC-N7 (1:1:1) and DH: EC-N7 (1:2) formulations showed the presence of DH in 
the microcrystalline aggregate needle form, which is distinguishable from other 
formulations. In case of EXTs of formulations of DH: EC-N7: MNT (1:2:0.1) and DH: 
Eudragit® RS PO (1:2) it was clear that the aggregates disappeared meaning an 
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amorphous DH within the hydrophobic matrices during the extrusion processing as it was 
confirmed by DSC results. In other words, no aggregation has been noticed suggesting a 
completely miscible single-phase binary solid dispersion system. SEM demonstrated that 
the process enables active ingredients to be embedded into an insoluble matrix since there 
is no any crystals on the surfaces but instead smooth surface.  
 
3.5. Conclusion 
    DH can be formulated in a solvent free-one step- cost effective- continuous process 
using C888 as a sustained release matrix with MNT as a hydrophilic pore former. It was 
confirmed that DH in lipid matrix is immiscible and it preserve its crystallinity during 
extrusion process. However, some fractions of DH are being solubilized in lipid matrix 
with no endothermic peaks, whereas formulations with MNT hasn’t maintained its 
crystallinity. The optimized formulation (DH: Lipid: Mannitol 1:2:0.075) demonstrated 
sustained, stable and complete release in 10 hours. Furthermore, in-vivo investigations are 
required to correlate with in-vitro dissolution studies for the development of optimum 
oral sustained release matrix tablets of DH which is the scope of next future study. The 
prepared tablets have shown good post compression characteristics regarding hardness, 
friability, weight drug, content and content uniformity, and desired and reproducible drug 
release profiles as compared to the reference commercial product. It has been concluded 
from the dissolution profiles that HME technique can be utilized for the manufacture of 
DH sustained release tablets by co processing of tablet excipients with API/C-888. 
Tailoring the ratio of C-888 and MNT in the formulations, along with an appropriate 
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extrusion temperature profile, resulted in modifying the release of DH and obtained the 
preferable release pattern. Co extrusion of tablet excipient (MCC) with API/matrix 
former could be a problem-solving approach for the development of lipid based 
hydrophilic APIs. This could contribute in the reduction of processing steps such as 
blending steps as well as improve the integrity of lipid-based tablets. HME processing 
temperature profile plays key factor in the dissolution behavior of DH. It has been 
demonstrated that co extrusion of tablets excipients within API/lipid matrix resulted in 
different dissolution behavior and tablet properties. Although DH in amorphous form in 
the case of formulation that contains hydrophilic diluents/fillers such as MNT and MCC, 
the release was sustained and stable. The only explanation is that these hydrophilic 
excipients are embedded within C-888 matrix. This new insight gives a new trend in 
terms of preparing a developed continuous tableting process (e.g. mini matrices) in solid 






















1 4 N/A 
Zone 2-3-4: 68 ºC 
Zone 5-6-7: 74 ºC 
Zone 8-9-10&die: 68 ºC 
50/100 rpm 
1 3 N/A 
1* 2* 
N/A or 0.1 or 
0.075 
1 1 N/A 
*(1:2) (DH:C-888): Also, processed by conventional heat fusion method at processing  
      temperature 100 ºC. 
 
 
Table 3-2: Formulation compositions and processing parameters for EC-N7 






















1 3 N/A N/A 0.05 
1 2 N/A 0.1 0.05 
1 1 N/A N/A 0.05 









Eudragit® RS PO (ratio 
w/w) 
Zone/Temp. Screw Speed 
1 4 









Table 3-4: HME processing conditions to study effect of HME processing     
temperature on lipid-based formulations drug release profile 
HME Parameters Processing Conditions 
Barrel Temperature Profiles (ºC) 
Zone 2-7: 77 ºC, Zone 8-10 & Die: 70 ºC 
Zone 2-7: 75 ºC, Zone 8-10 & Die: 70 ºC 
All zones: 70 ºC 






Table 3-5: Tablet compositions for conventional processed Tablets 300 mg tablet 
weight 
Material 







DH 8 23 7.67 23 
C-888 16 46 7.67 23 
Avicel® PH 102 
(MCC) 
75 228 83.66 251 
Magnesium Stearate 1 3 1 3 










Table 3-6: Tablet compositions for conventional processed Tablets 200 mg tablet 
weight  
Material 







DH 11.5 23 11.5 23 
C-888 23 46 11.5 23 
Avicel® PH 102 (MCC) * 64.5 129 76 152 
Magnesium Stearate 1 2 1 2 
Total 100 200 100 200 




Figure 3-1: DH/C-888 and DH/C-888/MNT DSC studies performed at 





Figure 3-2: DH/C-888 DSC studies performed at temperatures of 30-250 °C and 







Figure 3-3: DH/C-888/EC-N7(1:1:1) and DH/EC-N7(1:2) DSC studies performed 




Figure 3-4: DH/Eudragit® RS PO (1:2) and DH/EC-N7/MNT (1:2:0.1) DSC 





















                                              
                                       Figure 3-8: Effect of HME processing temperatures on the  

















           























        In the current research work, an attempt has been devised to enhance drug 
bioavailability and the therapeutic efficacy, reduce the drug administration frequency and 
improve patient compliance by developing a floating matrix mini tablet of APAP as well 
as to investigate the processed low-density polymers with regard to their high porosity 
and resultant floating efficiency. P-CO2 melt EXTs were successfully achieved using 
Eudragit® RS PO, Eudragit® RL PO, and Ethyl Cellulose EC-N7, with foamy and/or 
porous matrices. P-CO2/HME demonstrated promising in-vitro buoyancy efficiency and 
sustained release profiles. A comparison study with conventional method for preparing 
floating system has been done to test the efficiency of this proposed approach. Using this 
combined technology (P-CO2/HME), low-density floating devices can be designed and 
developed for other APIs/polymers. It overcomes the existing limitations commonly 
associated with other conventional techniques for manufacturing floating solid dosage 
forms. This study gives an important insight into combining HME/P-CO2 continuous and 
scalable technology for the development of floating devices, which may be useful for the 
large-scale production. In addition, it has been confirmed that DH extrudates with up to 
50% drug loading can be processed with C-888 maintaining the sustain release behavior 
and drug crystallinity even though with a highly soluble drug. Based on the initial 
screening studies and findings, C-888 were chosen as the main carrier for further 
77 
 
investigations to prepare DH tablet. Highly water-soluble drugs such as DH can be 
prepared as a sustained release formulation, with improved drug content and content 
uniformity while maintaining the drug’s crystallinity, using a twin-screw extrusion 
process employing the extrusion of premixed microcrystalline cellulose embedded within 
a hydrophobic matrix and a relatively low processing temperature profile. Tailoring the 
ratio of C- 888 ATO and MCC in the formulations, along with an appropriate extrusion 
temperature profile, can be utilized to modify the release of DH. Finally, the release 
profile of the optimized formulation of DH was similar to the marketed formulation with 
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